Feb-14 -

Gynecological Group

EORTC 44041 – A randomized, multicenter, phase III study of Erlotinib versus observation in patients with no evidence of disease progression after first line, platinum-based chemotherapy for high-risk Stage I and Stage II-IV ovarian epithelial, primary peritoneal, or fallopian tube cancer.

This EORTC study showed that in patients with stage I or II to IV epithelial ovarian, primary peritoneal, or fallopian tube cancer, the addition of the chemotherapy drug erlotinib (EGFR), did not improve progress free or overall survival. However, this study yielded valuable information on the mechanisms of EGFR and related pathways with targeted therapy in ovarian cancer patients.


Go to Top